- Fee assured
- Verified this account
This healthcare professional let us know that they are currently:
- Accepting new patients
- Available for:
- Phone consultations
- Video consultations
Last updated: 25 Jun 2020
- Home chemotherapy
Dr Jenner's main clinical interests are the diagnosis and management of haematological malignancies utilising chemotherapy, novel agents and high dose chemotherapy and stem cell transplantation. He leads the myeloma team at UHS with direct responsibility for clinical management of myeloma and paraprotein-related disorders including AL amyloidosis and POEMS syndrome. He runs a weekly all day myeloma clinic for this patient group and accepts referrals both from primary care as well as referrals from other hospitals for specialist input including for clinical trials and transplantation. He also chairs the Central South Coast (Western) Leukaemia and Myeloma multidisciplinary team meeting.
Areas of interest
Myeloma; Plasma cell disorders including AL amyloidosis; Lymphoproliferative disorders; Leukaemia; Haematopoietic stem cell transplantation
Current NHS consultant posts held
Consultant Haematologist at University Hospital Southampton (UHS) NHS Foundation Trust since November 2009.
Haematology Clinical Lead at UHS March 2012 to present.
Dr Jenner is principal investigator of a portfolio of myeloma clinical trials encompasing all stages of the disease.
Dr Jenner undertook 4 years of research in to the genetics abnormalities within myeloma at the Institute of Cancer Research and Royal Marsden Hospital between 2005 and 2009. He continues to have an active interest in the role of genetic abnormalities in myeloma and their impact on treatment outcomes.
Bird, JM., Owen, R.G., D’Sa, S., Snowden, J.A., Pratt, G., Ashcroft, J., Yong, K., Cook, G., Feyler, S., Davies, F.E., Morgan, G.J., Cavenagh, J., Low, E., Behrens, J., Jenner, M.W. on behalf of the Haemato-oncology Task Force of the British Committee for Standards in Haematology. Guidelines for the diagnosis and management of myeloma 2013. Online publication: http://www.bcshguidelines.com/documents/MYELOMA_GUIDELINE_updated_29_aug_RG_jzw_(3).pdf
Publicover, A., Richardson, D. S., Davies, A., Hill, K. S., Hurlock, C., Hutchins, D., Jenner, M. W., Johnson, P. W., Lamb, J., Launders, H., McKeag, N., Newman, J. and Orchard, K. H. (2013), Use of a biosimilar granulocyte colony-stimulating factor for peripheral blood stem cell mobilization: an analysis of mobilization and engraftment. Br J Haematol, 162: 107–111.
Jenner, M.W. & Morgan, G.J.. Plasma cell neoplasms. In: Magrath, I, editor. The Lymphoid Neoplasms. London: Hodder Arnold. 2010.
Schey, S.A., Morgan, G.J., Ramasamy, K., Hazel, B., Ladon, D., Corderoy, S., Jenner, M., Phekoo, K., Boyd, K. & Davies, F.E. (2010) The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study. Br J Haematol, 150, 326-333.
Walker, B.A., Leone, P.E., Chiecchio, L., Dickens, N.J., Jenner, M.W., Boyd, K.D., et al (2010) A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood, 116, e56-65.
Davies, F.E., Wu, P., Jenner, M., Srikanth, M., Saso, R. & Morgan, G.J. (2007) The combination of cyclophosphamide, velcade and dexamethasone induces high response rates with comparable toxicity to velcade alone and velcade plus dexamethasone. Haematologica, 92, 1149-1150.
Jenner, M.W., Leone, P.E., Walker, B.A., Ross, F.M., Johnson, D.C., Gonzalez, D., et al (2007) Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma. Blood, 110, 3291-3300.
Morgan, G.J., Schey, S.A., Wu, P., Srikanth, M., Phekoo, K.J., Jenner, M. & Davies, F.E. (2007) Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients. Br J Haematol, 137, 268-269.
Morgan, G.J., Krishnan, B., Jenner, M. & Davies, F.E. (2006) Advances in oral therapy for multiple myeloma. Lancet Oncol, 7, 316-325.
Courses offered to GPs
- MBBS Newcastle upon Tyne 1997
- MRCP (UK) Royal College of Physicians of London 2000
- FRCPath Royal College of Pathologists 2008
Reference number 4442130
Details of entry to specialist register
- GMC Specialist Register Haematology, 2009
- Spire Southampton Hospital Chalybeate Close...
- 18:00 - 20:00
- 023 8076 4390
Post treatment communication
Following treatment of a Bupa member, I will communicate with GPs in line with Department of Health, GMC and appropriate professional bodies guidelines.